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Sex Hormone Binding Globulin (SHBG) is the major serum carrier of sex hormones. However, growing evidence suggests that
SHBG is internalised and plays a role in regulating intracellular hormone action.This study was to determine whether SHBG plays
a role in testosterone uptake, metabolism, and action in the androgen sensitive LNCaP prostate cancer cell line. Internalisation
of SHBG and testosterone, the effects of SHBG on testosterone uptake, metabolism, regulation of androgen responsive genes,
and cell growth were assessed. LNCaP cells internalised SHBG by a testosterone independent process. Testosterone was rapidly
taken up and effluxed as testosterone-glucuronide; however this effect was reduced by the presence of SHBG. Addition of SHBG,
rather than reducing testosterone bioavailability, further increased testosterone-induced expression of prostate specific antigen and
enhanced testosterone-induced reduction of androgen receptor mRNA expression. Following 38 hours of testosterone treatment
cell morphology changed and growth declined; however, cotreatment with SHBG abrogated these inhibitory effects.These findings
clearly demonstrate that internalised SHBG plays an important regulatory and intracellular role in modifying testosterone action
and this has important implications for the role of SHBG in health and disease.
1. Introduction
Sex Hormone Binding Globulin (SHBG) is the major sex
hormone carrier protein in serum. Under physiological
conditions, approximately 70% of testosterone (Te) is bound
to SHBG with high affinity, about 20–30% is weakly bound
to albumin, and the remaining 1-2% is free [1, 2]. Pubertal
increases in serum testosterone in males peak at 20 years of
age and remain stable until the eighth decade. After child-
hood, SHBG declines by the age of 20 years and then remains
stable until the sixth decade with a gradual, progressive rise
thereafter [3].
For many years it has been widely accepted that the pri-
mary function of SHBG is to transport sex steroid hormones
to target tissues where SHBG modulates the level of free sex
hormones that can enter target cells [4, 5]. However, in recent
years, additional roles for SHBGhave been identified.There is
strong evidence that SHBG mediates steroid hormone signal
transduction at the plasma membrane [6] and a growing
body of evidence that SHBG may be taken up by cells
and have intracellular biological functions [7]. A study has
demonstrated that SHBG is internalised through theMegalin
receptor in rat yolk sac cells and that Megalin deficient mice
display defects similar to animals treated with androgen- or
estrogen-receptor antagonists [4]. SHBG internalisation has
also been described in other cell types such as periventricular
neurons and fibroblast cells, suggesting that it may have an
intracellular role [8, 9]. Intracellular expression of SHBG
in mouse proximal tubule cells has been demonstrated to
increase uptake of 3H-dihydrotestosterone (DHT) and to
prolong the expression of androgen responsive genes [10].
This study was designed to determine whether the andro-
gen sensitive LNCaP prostate cancer cell line [11] internalises
SHBG; whether SHBG uptake affects Te uptake; the effects
of SHBG on Te function and metabolism; and the effects of
SHBG and Te on cell growth.
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2. Materials and Methods
2.1. Cell Culture. The androgen responsive human prostate
cancer cell line LNCaP clone FGC (ATCC, VA, USA)
was chosen for this study. Cells were cultured in Roswell
Park Memorial Institute (RPMI) medium (Sigma-Aldrich,
VIC, Australia) supplemented with 10% fetal bovine serum
(FBS), 500U/mL penicillin streptomycin (Gibco, VIC, Aus-
tralia), and 5 𝜇g/mL plasmocin (InvivoGen, VIC, Aus-
tralia) in a conventional cell culture incubator. All experi-
ments were conducted in serum-free medium to eliminate
SHBG and albumin contamination from FBS and in the
absence of phenol red, which can bind to steroid receptors
[12].
2.2. Reagents. Purified native human SHBG protein was
purchased from Fitzgerald Industries International, MA,
USA. SHBGwas purified from the serum of pregnant women
by ligand affinity chromatography with a purity of >98%
with an unspecified residual steroid content. Testosteronewas
purchased from Sigma-Aldrich, VIC, Australia, and prepared
as a 500mM stock in ethanol. Testosterone was diluted >5 ×
106 times in serum-free medium (final < 0.00002% ethanol)
and used at a maximal final concentration of 100 nM in
experiments. Ethanol had no effects on LNCaP cell growth at
concentrations between 0.00001% and 1% over 96 hours (data
not shown).
Unless specified all other reagents were purchased from
Sigma-Aldrich.
2.3. Alexa Fluor 546 SHBG Labeling and Internalisation.
Purified native human SHBG protein was labeled using an
Alexa Fluor 546 Protein LabelingKit (Life Technologies, VIC,
Australia). Briefly, 1mL of 2mg/mL purified SHBG protein
was incubated with Alexa Fluor 546 reactive dye for 2 hours
at room temperature. Then Alexa Fluor 546 labeled-SHBG
(Alexa546-SHBG) was purified through a Bio-Gel P-6 Gel
column (BioRad, CA, USA). To determine the concentration
of labeled SHBG and the degree of fluorescent labeling, the
conjugate solution was measured at 280 nm and 540 nm in a
Nanodrop 2000 spectrophotometer (Thermo Scientific, NC,
USA).
For Alexa546-SHBG uptake experiments, the cells were
serum-starved for 1 hour and then incubated in 125 nM
Alexa546-SHBG ± 25 nM Te in serum-free RPMI for 1 hour
at room temperature. Cells were washed with Phosphate
Buffered Saline (PBS), fixed in 2% paraformaldehyde, and
permeabilised in 0.2% Triton X-100 in PBS. Cells were
costained with Alexa488-phalloidin to highlight the 𝛽-actin
skeleton and nuclei were stained with DAPI. Coverslips
were mounted with Prolong Gold Antifade reagent. Images
were captured using a DeltaVision Deconvolution Micro-
scope (Applied Precision, Washington DC, USA). Uptake of
Alexa546-SHBG was confirmed by costaining internalised
Alexa546-SHBG with a monoclonal anti-SHBG antibody
(Sigma, VIC, Australia) conjugated to an Alexa488 labeled
secondary antibody.The colocalisation of Alexa546 (red) and
Alexa488 (green) discriminated Alexa-SHBG from endoge-
nous SHBG, which was stained with Alexa488 only. Treat-
ments with serum-free medium only and Alexa546 dye only
were used as negative controls.
SHBG secretion from LNCaP cells was not detectable
(data not shown) by Western blot or Unicel immunoassay
(lower limit of detection< 2 nM), despite cell culturemedium
being concentrated 12-fold; therefore endogenous levels of
SHBG should have little effect on our experiments using
125 nM SHBG.
2.4. Measurement of Te Uptake by TandemMass Spectrometry.
Cells were cultured in 6-well plates and serum-starved
for 4 hours prior to uptake experiments. Cells were then
incubated in serum-free uptake medium containing 25 nM
(30 pmoles/well) of Te ± 125 nM SHBG for 1, 4, and 24 hours.
Control cells were in culture medium only. At the end of
each time point the culture medium was collected for Te
measurements. Cell monolayers were washed carefully with
2mL PBS (pH 7.3) and then cells were lysed with Pierce
M-PER Mammalian Protein Extraction Reagent (Thermo
Fisher Scientific) to extract soluble protein. Further lysis
with Pierce RIPA Lysis and Extraction Buffer (Thermo Fisher
Scientific) was used to extract remaining proteins from the
membrane andnuclei. Tewasmeasured in the original uptake
medium (25 nM), cell culture medium, and cell lysates using
Tandem Mass Spectrometry. Te measured in all fractions
was expressed as a percentage of the Te in the original
uptake medium. Cellular Te includes all Te measured in both
lysates including cytosol, membrane, and nuclei. Total Te
includes all Te measured in cellular fractions and cell culture
medium.
Liquid Chromatography followed by TandemMass Spec-
trometry (LC MSMS) was used to measure Te on a Waters
Ultra Performance Liquid Chromatography (UPLC) Acquity
system. Briefly, samples (in 2mL 96 deep well plates)
were precipitated with 3 volume equivalents of 50mM
zinc sulphate/40% methanol containing an internal standard
(testosterone d2). After protein precipitation, the samples
were centrifuged and the plate was transferred to an autosam-
pler. An aliquot of 50 𝜇L was injected onto a Waters Online
Sample Manager (OSM). The extract was concentrated onto
the MassTrak XBridge C18 OSM 10 𝜇m cartridge, washed
with 30% methanol, and then switched into line and eluted
directly into the UPLC system. The analytes were separated
on an Acquity BEH C
18
2.1 × 50mm column. The column
eluent was directed (without stream splitting) into the ion
source of a Waters Xevo TQ-D tandem quadrupole MS,
operated in positive ESI mode. The following quantifier and
qualifier transitions were utilised: testosterone (289.1 > 97.0,
289.1 > 109.0) and testosterone d2 (291.1 > 111.0).The gradient
was returned to initial conditions in preparation for the next
sample, which is being prepared in parallel by the OSM.
Cycle time between samples is 3min. The limit of the blank
was 0.04 nmol/L with an interrun imprecision of 9.8% for
testosteroneat 0.9 nmol/L.
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2.5. Deconjugation of Te-Glucuronide. Measurement of Te-
glucuronide formation and efflux into medium was deter-
mined by digestion of cell culture medium with E. coli 𝛽-
glucuronidase (Sigma, VIC, Australia), followed by mea-
surement of Te by LC MSMS. Enzymatic deconjugation of
Te-glucuronide was optimised by using two different con-
centrations of 𝛽-glucuronidase (200U/mL and 400U/mL),
two different dilutions of sample (culture medium neat
and diluted 1 : 10) for 24 hours incubation time. Maxi-
mal deconjugation was achieved in neat samples incubated
with 200U/mL 𝛽-glucuronidase for 24 hours at 37∘C. Te-
glucuronide was not detectable in cell lysates; therefore
only effluxed Te-glucuronide in cell culture medium was
measured.
After culturing cells with 25 nM (30 pmoles/well) Te ±
125 nM SHBG for 4 or 24 hours, culture medium was diluted
in an equal volume of 0.25M potassium phosphate buffer,
pH 6.9 ± 200 units/mL of E. coli 𝛽-glucuronidase (Sigma,
VIC, Australia) and incubated at 37∘C for 24 hours [13]. To
quantitate the amount of Te-glucuronide, two sets of identical
samples were prepared with or without 𝛽-glucuronidase.
The quantity of Te in each sample was measured by LC
MSMS and expressed as a percentage of Te in the original
uptake medium. Unconjugated Te was detectable before
digestion with 𝛽-glucuronidase. Following treatment with
𝛽-glucuronidase both unconjugated and previously glu-
curonidatedTeweremeasured; therefore the value for uncon-
jugated Te was subtracted from this in order to quantify the
glucuronidated fraction.
2.6. Quantitative Real-Time PCR (RT-PCR). Total RNA was
isolated using anRNeasyMiniKit (QIAGEN,VIC,Australia).
RNA concentrations and quality were determined using a
NanoDrop-3000 Spectrophotometer (NanoDrop Technolo-
gies, Inc., NC, USA). Four micrograms of total RNA was
reverse-transcribed with 200 units of Superscript III Reverse
Transcriptase (Invitrogen Life Technologies, CA, USA)
and 0.5 𝜇g of oligo (dT) 15 primers (Roche Diagnostics,
Mannheim,Germany) in a reaction volumeof 20𝜇L. RT-PCR
was performed using 3𝜇L of cDNA (represented 6 ng RNA),
0.5 𝜇M of each primer (Table 1), and FastStart SYBR green
PCR Master (Roche Diagnostics, Mannheim, Germany) in a
Rotor Gene RG-6000 (Corbett Research, NSW, Australia). To
quantify the gene expression profile in each sample, the
efficiency of each standard curve was determined by its slope
and comparative threshold. Data were presented as ratio of
the amount of targeted mRNA (arbitrary units) normalised
with the house-keeping gene beta 2-microglobulin (𝛽2M)
2.7. Quantification of Alexa546-SHBG Uptake. LNCaP cells
(∼80,000 cells/well) were cultured on 24-well plates for 48
hours. Following serum starvation, cells were incubated with
combinations of Alexa546-SHBG ± Te and imaged using
an IncuCyte ZOOM Live Cell-Imaging System (Essen
BioScience, MI, USA) with phase and red channels and
scanned at 3-hour intervals for a total of 30 hours. At the end
of the incubation period, cells werewashed in an acid solution
(200mM glycine, 150mM NaCl, pH 2.5) to remove surface
bound Alexa546-SHBG [14]. IncuCyte ZOOM software was
used to quantify the red objects in 9 nonoverlapping images
per well. Data were presented as mean number of red objects
per image.
2.8. Cell Growth Assay. LNCaP cells were cultured on 24-well
plates with ∼35,000 cells per well. After serum starvation the
cells were treated with various combinations of Te ± SHBG
and incubated in an IncuCyte ZOOM set to scan every 3
hours for up to 86 hours. The kinetic measurements of pro-
liferation and data analysis were performed using IncuCyte
ZOOM software according to manufacturer’s instructions.
Mean values of percentage confluence were calculated using
9 nonoverlapping images per well. The data was presented as
percentage of phase object confluence.
2.9. Statistical Analysis. Statistical analysis was performed
using GraphPad Prism Software (GraphPad Software, Inc.,
CA, USA). Comparison between groups was determined
by one-way ANOVA with Tukey’s test. 𝑃 values of ≤0.05
were considered significant. All experiments were repeated
at least three times on separate cell cultures and performed in
triplicate for each treatment group.
3. Results
3.1. Internalisation of Alexa546-SHBG. Two methods were
used to quantify Alexa546-SHBG uptake. Firstly, after incu-
bation with Alexa546-SHBG, the cells were imaged using
DeltaVision deconvolution microscopy (Figure 1(a)). Inter-
nalisation of Alexa546-SHBG was confirmed by generating
an orthogonal view and a series of 𝑧-stack images. The
red fluorescent signal representing Alex546 labeled SHBG
was observed in the cells incubated with Alexa546-SHBG
(Figure 1(a)(3)). There was no red signal observed in the
negative controls incubated with unconjugated Alexa546 dye
(Figure 1(a)(2)), confirming that Alexa-546 SHBG and not
the Alexa dye itself was internalised by the cells. Additionally
the internalised Alexa546-SHBG (red) colocalised with an
Alexa488 (green) labeled anti-SHBG antibody (Figure 1(b))
further proving that SHBG was internalised while still being
conjugated to Alexa546 dye. Endogenous SHBG is stained
only with the Alexa488 anti-SHBG antibody (green). Sec-
ondly, to quantitate internalised Alexa546-SHBG IncuCyte
ZOOM technology was used. A dose dependent uptake of
Alexa546-SHBG was observed (Figure 1(c)). Addition of Te
had no significant effect onAlexa-SHBGuptake (Figure 1(d)).
Veryweak signalwas detected inAlexa546 dye treated culture
and after the acid wash, no signal was detected.
3.2. Effect of SHBG on Te Uptake. Incubation with 25 nM Te
for 1, 4, and 24 hours resulted in rapid uptake of Te followed
by a decline in cellular levels (Figure 2(a)). Cellular Te levels
peaked at one hour (17.84 ± 0.31%) and then declined to
14.31±0.93%and 5.95±0.31%by 4 and 24 hours, respectively
(Figure 2(a)). In contrast, in the presence of 125 nM SHBG,
cellular Te levels were lower at 1 hour (1.10 ± 0.31%) and
steadily increased to 1.32±0.003% and 2.64±0.04% by 4 and
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Table 1: Primer sequences for quantitative RT-PCR.
Gene name Primers Location GenBank accession number
PSA (F) 5
󸀠-GTGTGTGGACCTCCATGTTATT-3󸀠
(R) 5󸀠-TGCCCCATGACGTGATACCT-3󸀠
516-537
691-672 NM 001648
AR (F) 5
󸀠-GGCTGTCATTCAGTACTCCTG-3󸀠
(R) 5󸀠-GG AGC CAT CCA AAC TCT TGA-3󸀠
3320-3340
3491-3510 NM 000044
SHBG (F) 5
󸀠-GCCCAGGACAAGAGCCTATC-3󸀠
(R) 5󸀠-CCTTAGGGTTGGTATCCCCATAA-3󸀠
149-168
277-255 NM 001146281
B2M (F) 5
󸀠-GGCTATCCAGCGTACTCCAAA-3󸀠
(R) 5󸀠-CGGCAGGCATACTCATCTTTTT-3󸀠
57-77
302-281 NM 004048
Reference: http://pga.mgh.harvard.edu/primerbank/index.html.
(F): forward; (R): reverse; PSA: prostate specific antigen; AR: androgen receptor; SHBG: sex hormone binding globulin.
24 hours. At 24 hours, cellular Te levels in cells incubatedwith
Te plus SHBG were approximately half that of cells treated
with Te alone.
Figure 2(b) shows the total Te measured in both the cell
lysates and cell culture medium. When LNCaP cells were
cultured in Te alone, 93 ± 2.80% of Te from the original
uptake medium was measured at 1 hour but decreased to
55.50 ± 4.36% and then 16.79 ± 0.93% by 4 and 24 hours,
respectively. When cells were cultured in Te plus SHBG, Te
measurements did not change significantly over the three
time points (72.69 ± 0.62%, 77.31 ± 0.93%, and 74.23 ± 0.93%
at 1, 4, and 24 hours, resp.). Dihydrotestosterone was not
detected in any of the samples.
3.3. Te-Glucuronide Formation. Cells were exposed to 25 nM
Te ± 125 nM SHBG for 4 and 24 hours; then cell culture
medium was collected and treated with 𝛽-glucuronidase.
When LNCaP cells were cultured in Te for 4 hours, 50.73 ±
3.51% of Te was glucuronidated and effluxed and only
11.12±1.06%of Te was unconjugated (Figure 2(c)). However,
when SHBG was also added, only 4.41 ± 2.1% of Te was
glucuronidated and 60.84 ± 1.93% of Te was unconjugated.
Following 24 hours in culture with Te, LNCaP cells had
glucuronidated and effluxed 67.07 ± 5.48% of Te and only
3.8 ± 1.59% remained unconjugated. Again, less Te was
glucuronidated when cells were incubated with Te and SHBG
for 24 hours with 13.19 ± 4.93% of Te glucuronidated
compared to 67.11 ± 11.74% unconjugated.
3.4. Effect of Te and SHBG on LNCaP Cell Growth. LNCaP
cells were seeded at initial 20% confluence and after 38 hours
of culture cell confluency reached about 35–40% with no
differences between treatment groups (Figure 3(a)(A)). Cells
grewwell in serum-freemedium for up to 86 hours. Exposure
to only SHBG did not alter cell growth. However after 38
hours in culture, growth declined in a dose dependent man-
ner in those cells treated with 1, 25, and 100 nM Te. Addition
of either 25 or 125 nM SHBG canceled the inhibitory effects
of Te in a dose dependent fashion (Figures 3(B) and 3(C)).
Moreover, cells cultured in Te alone displayed morphological
changes in that cells became rounded rather than spread out
and detached from the culture plate (Figure 3(b)(B)). Control
cells and those incubated with Te plus SHBG did not have
these morphological changes (Figures 3(b)(A) and 3(b)(C)).
3.5. Effect of SHBG on Te-Sensitive Gene Expression. Fig-
ure 4(a) displays a paired comparison of treatment of LNCaP
cells with 0, 1, 10, and 25 nM Te alone and with the addition
of 25 nM of SHBG for 24 hours. Surprisingly, addition of
SHBG, despite having previously been shown to reduce
Te uptake, significantly enhanced Te upregulation of PSA
mRNA expression at Te concentrations of 10 and 25 nM (𝑃 <
0.0001) (Figure 4(a)). When cells were incubated with 25 nM
SHBG plus 0, 1, 5, 10, and 25 nM Te (Figure 4(b)), expression
of PSA was increased by Te (𝑃 < 0.0001). When cells were
incubated with 10 nM Te with 0, 10, 25, or 50 nM SHBG,
PSA mRNA expression increased with increasing amounts
of SHBG to a maximum at 25 nM SHBG (𝑃 < 0.001)
(Figure 4(c)).
In the same samples, androgen receptor (AR) mRNA
expression was decreased by Te and expression was further
decreased by the addition of 25 or 50 nMSHBG (Figure 4(d)).
SHBG mRNA expression was significantly decreased by Te
(𝑃 < 0.0001) (Figure 4(e)). Additionally, SHBG further
decreased the Te downregulation of SHBG expression at all
SHBG concentrations; however this did not reach statistical
significance.
4. Discussion
The primary role of hepatically produced SHBG as a serum
carrier of sex hormones is well documented [5, 15]. SHBG
expression has also been demonstrated in sex hormone target
tissues such as human prostate [16, 17], LNCaP cells [18],
testes, duodenum, ovary, placenta, proximal tubule epithelial
cells (PTEC), and cerebral cortex as well as several cancers
[10, 15, 19–21]. Higher expression of SHBG in prostate cancer
tissue is associated with poor clinicopathological features
suggesting a role in prostate cancer progression [22], perhaps
due to prolonged expression of androgen responsive genes
[10]. It has also been proposed that locally regulated and
produced SHBG may be destined to participate in signalling
at the prostate cellmembrane [19]. Using a variety of technical
approaches we have confirmed that LNCaP cells take up
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Figure 1: (a) Internalisation of Alexa Fluor 546 labeled SHBG (Alexa-SHBG) by LNCaP cells using a DeltaVision DeconvolutionMicroscope.
Cells were incubatedwith (1) serum free RPMImedium, (2) Alexa 546 dye, and (3) Alexa Fluor 546 labeled SHBG (red) in serum-freemedium
for 1 hour and then costainedwithAlexa Fluor 488 phalloidin (green) to outline the actin cytoskeleton andDAPI (blue) to localise nuclei. Bar =
10𝜇m. (b) To confirm Alexa labeled SHBG protein internalisation, cells were incubated with Alexa-SHBG for 1 hour and then costained with
mouse anti-SHBG monoclonal antibody conjugated with anti-mouse Alexa Fluor 488 secondary antibody (green). (1) Internalised Alexa-
SHBG (red) was detected inside the cells. (2) Intracellular SHBG was detected by anti-SHBG antibody (green). (3) Merged images (1) and
(2) show internalised Alexa-SHBG in orange and endogenous SHBG in green. Bar = 10𝜇m. (c) Alexa-SHBG uptake by LNCaP cells is dose
dependent.The cells were incubated with 5 nM (closed circle), 25 nM (open square), 50 nM (open triangle), and 100 nM (cross) Alexa-SHBG
for 30 hours. Data presented as mean number of red objects counted per image. Imaged using IncuCyte ZOOMLive Cell Imaging System. (d)
Quantitation of Alexa-SHBG uptake by LNCaP cells using the IncuCyte ZOOM Live Cell Imaging System. Untreated LNCaP cells (control,
closed diamond) and LNCaP cells treated with Alexa-546 dye only (dye, open square) were used as negative controls. Cells were starved with
serum-free RPMI for 1 hour and treated with 50 nM Alexa546-SHBG only (closed triangle) and with 10 nM testosterone (Alexa-SHBG + Te,
closed circle). Data presented as mean number of red objects counted per image.
SHBG in a dose dependent but not androgen dependent
manner.
It is well known that SHBG reduces cellular uptake of Te;
howeverwe have demonstrated that SHBGmay alsomaintain
stable levels of biofunctional Te and physiologically relevant
intracellular Te levels by reducing Te glucuronidation and
efflux. Another study has also demonstrated that LNCaP cells
incubated in 30 nMDHT glucuronidated 85% of the DHT in
5 days. Upon addition of 140 nM SHBG, 95% of DHTwas not
taken up by cells and remained in themedium [23].This rapid
inactivation of Te by glucuronidation has been demonstrated
in human clinical studies, where a single oral dose of Te did
not alter serum total Te levels but rapidly and significantly
increased levels of conjugated Te in serum [24]. However we
acknowledge that the level of free Te in healthy men is much
lower (174–729 pmol/L [25]) than that used in this study, since
in vivo SHBG is always present. When SHBG is reduced or
absent, excess free Te may enter cells and oversaturate the
ARs since it has been reported that AR saturation occurs at
approximately 2-3 nM in prostate [26]. The LNCaP cells may
respond to this by rapidly glucuronidating and effluxing the
excess Te.The steroid content of SHBG (Fitzgerald Industries
International) was not specified; however it was purified from
the serum of pregnant women which contains significantly
lower Te than that of adult males [3, 27]. Even if all of
the serum Te were carried over, the Te at the maximum
SHBGconcentrations used (125 nM)would bemuch less than
1 nM, significantly less than that used in our experiments.
Importantly, SHBG treatment had no significant effect on
gene expression when compared to untreated controls.
To further explore the intracellular biological actions of
SHBG the effects of SHBGonTe responsive genes were inves-
tigated. As expected Te upregulated PSA mRNA expression.
However, despite the significantly lower intracellular Te in the
presence of SHBG, addition of SHBG in combination with
Te further increased the expression of PSA mRNA. Similarly,
downregulation of AR mRNA expression by Te was also
further enhanced when cells were incubated with SHBG and
6 International Journal of Endocrinology
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Figure 2: Effect of SHBG on testosterone uptake and metabolism by LNCaP cells measured by Liquid Chromatography/Tandem Mass (LC
MSMS) Spectrometry. LNCaP cells were treated with 25 nM Te ± 125 nM SHBG (S) for 1, 4, and 24 hours. (a) Cellular Te and (b) total Te in
culture medium and cell lysates (undigested). (c) Measurement of unconjugated (black) and glucuronidated (grey) Te in cell culture medium.
Eachmedium samplewas divided into two equal volumes anddigestedwith orwithout 200 units/mL𝛽-glucuronidase in potassiumphosphate
buffer (pH 6.9) for 24 hours at 37∘C to revert glucuronidated testosterone to unconjugated testosterone. All measurements are expressed as a
percentage of Te in the original uptake medium.
Te. Addition of SHBG also further decreased the Te downreg-
ulation of SHBG mRNA although, under these conditions,
the reduction did not reach statistical significance. In this
experiment the cellular Te level was lower in the presence of
SHBG than when Te was added alone; however the effects
on gene expression were much greater. Moreover, maximal
effects on gene expression were reached at a lower concentra-
tion of Te when SHBG was present. Intracellular expression
of SHBG inmouse proximal tubule cells has also been shown
to prolong the expression of androgen responsive genes
[10] and overexpression of SHBG in LNCaP cells has been
shown to influence the expression of estrogen and andro-
gen responsive genes [28]. This would suggest that both
endogenously expressed SHBG and internalised SHBG have
similar positive stimulatory effects on androgen sensitive
gene expression.
In our in vitro study, Te decreased SHBG gene expression.
A downregulation of serum SHBG also occurs in healthy
men following Te administration [29]. We speculate that, in
pathological conditions where serum SHBG is reduced, for
example, in overweight and obese men [30–33], Te uptake,
glucuronidation, and efflux would be increased potentially
exacerbating Te deficiency.
In the present study Te treatment did not promote cell
growth, and in fact a dose dependent inhibition of growth
was demonstrated after 38 hours in culture. Coincubation
with SHBG prevented the Te inhibition of cell growth.
A biphasic effect on cell proliferation has previously been
described where proliferation was increased up to 0.3 nM
DHT and then progressively decreased when concentrations
were raised above 0.3 nMDHT [23, 34]. The inhibitory effect
of DHT was abrogated by addition of human serum [34]
or SHBG [23]. The effect of the synthetic androgen methyl-
trienolone (R1881), which binds poorly to SHBG, was not
affected by addition of SHBG [23]. Other synthetic andro-
gens displayed a similar inhibitory effect in LNCaP cells
resulting in morphological changes and inhibition of colony
formation; however these effects were not reproduced in
the androgen receptor-negative prostate cells lines PC-3,
DU145, and MRC-5. Furthermore, addition of antiandro-
gen drugs (6-chloro-6-dehydro-17x-acetoxy-hla, cyproterone
acetate, and hydroxyflutamide) restored LNCaP cell growth
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Figure 3: Effects of testosterone and SHBG on LNCaP cell growth and morphology: (a) growth measured using the IncuCyte ZOOM Live
Imaging System. LNCaP cells were treated with ((a)(A)) 0, 1, 25, and 100 nM testosterone (Te) in serum-free medium, ((a)(B)) 25 nM Sex
Hormone Binding Globulin (SHBG) plus 0, 1, 25, and 100 nM testosterone in serum-free medium, and ((a)(C)) 125 nM SHBG plus 0, 1, 25,
and 100 nM testosterone in serum-free medium. Measurements gathered over 86 hours without changing medium. Values are expressed as
mean percentage phase object confluence using 9 nonoverlapping images per well. (b) Morphology assessed by IncuCyte Imaging. Cells were
imaged after 86 hours in culture using IncuCyte ZOOM Live Imaging System. ((b)(A)) LNCaP cells cultured in serum-free medium were
used as the normal control. ((b)(B)) Cells treated with 25 nM testosterone only and ((b)(C)) cells treated with 25 nM testosterone plus 125 nM
SHBG. Bar = 50 𝜇m.
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Figure 4: Effects of testosterone (Te) and Sex Hormone Binding Globulin (SHBG) on prostate specific antigen (PSA), androgen receptor
(AR), and SHBG mRNA expression in LNCaP cells by quantitative Real-Time PCR. (a) PSA mRNA expression in cells treated with 0, 1, 10,
and 25 nMTe± 25 nMSHBG for 24 hours. (b) PSAmRNAexpression in cells treatedwith 25 nMSHBGplus 0, 1, 5, 10, or 25 nMTe. Expression
of PSA (c), AR (d), and SHBG (e) mRNA in LNCaP cells treated with 10 nM Te plus 0, 10, 25, or 50 nM SHBG for 24 hours. All experiments
were performed at least three times in triplicate. The mRNA expression was normalised to the housekeeping gene, 𝛽2-microglobulin (B2M).
One-way ANOVA with Tukey’s test was used for statistical analysis. Tukey’s test indicated as “no significance” (ns) or asterisk (∗𝑃 < 0.05;
∗∗∗𝑃 < 0.001; and ∗∗∗∗𝑃 < 0.0001). All results were represented as mean ± standard error (SEM).
[35]. All of these studies suggest that inhibition is through
an AR pathway. In the present study the striking changes in
cell morphology suggest that the cells may be stressed,
perhaps due to the requirement to glucuronidate high lev-
els of intracellular Te; however previous studies have not
included descriptions of cell morphology in order to make a
comparison.Themechanism by which Te inhibits cell growth
in LNCaP cells after 38 hours is unknown. Regardless of the
percentage of cell confluence at the beginning of treatment, Te
always caused morphological changes (data not shown).This
perhaps suggests that Te had an effect on cellmorphology and
attachment rather than directly on cell proliferation. How-
ever, the inhibition of cell growth by Te warrants further
investigation.
5. Conclusions
In this study we have demonstrated that in the absence of
SHBG large amounts of Te rapidly enter the cell where they
are inactivated by conjugation to glucuronic acid and
effluxed. In the presence of SHBG however, while there is
reduced Te uptake, glucuronidation and efflux of Te are also
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reduced and the effects of Te on androgen responsive genes
are enhanced.This in vitro study of the role of SHBGmayhave
significant clinical relevance, and as such, the assessment of
androgen deficiency in vivo should simply rely not only on
measurements of total Te alone but also on the evaluation of
serum SHBG levels.
These findings clearly demonstrate that SHBG plays an
important regulatory and intracellular role to modify Te
metabolism and function and to promote cell growth. These
observations will need to be confirmed in other androgen
sensitive tissues. If a consistent effect is demonstrated, it will
significantly change our current understanding of the role of
SHBG in health and disease.
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